久久久国产一区二区_欧美在线小视频_高清一区二区三区_久久综合久久久_成人久久久久久久久_亚洲精品视

上海非利加實業有限公司Logo

熱門詞: 進口電動溫度調節閥結構圖|進口電動溫度調節閥數據表進口電動高溫調節閥-德國進口電動高溫法蘭調節閥進口電動蒸汽調節閥-德國進口電動蒸汽調節閥

當前位置: 首頁 > 所有品牌 > Psivida
Psivida
Psivida Psivida

美國Psivida  
pSivida是一個發展中的小型化,注射,藥物輸送系統的領導。我們開發產品,以治療嚴重或危及生命的疾病,單獨或與其他公司合作。我們已經開發出的設備是如此之小,他們是FDA批準進入眼內的管理,一旦管理他們釋放其藥物的幾個月甚至幾年。

pSivida is a leader in the development of miniaturized, injectable, drug delivery systems. We develop products to treat serious or life threatening diseases alone or in partnership with other companies. We have developed devices that are so small they are FDA approved to be administered into the eye and once administered they release their drug for months and years.
pSivida's lead development product, ILUVIEN?, delivers fluocinolone acetonide (FA). It is designed to be injected into the eye to provide sustained release into the back of the eye for up to three years after a single injection. ILUVIEN has completed two three-year Phase III clinical trials in Diabetic Macular Edema, one of the leading causes of blindness in the developed world. The NDA was submitted to the FDA in May 2011 by our licensee Alimera Sciences and the review is expected to be completed by the end of 2011. ILUVIEN is also in Phase II clinical trials in dry age-related macular degeneration, wet age-related macular degeneration and retinal vein occlusion. These studies are being conducted by Alimera Sciences.
pSivida's two FDA approved sustained release products to treat chronic back of the eye diseases are Retisert? for the treatment of posterior uveitis and Vitrasert? for the treatment of AIDS-related cytomegalovirus (CMV) retinitis. pSivida has licensed both of these products and the technologies underlying them to Bausch & Lomb Incorporated. Vitrasert and Retisert provide sustained release for six to nine months and two and a half years, respectively.
pSivida has a world wide collaborative Research and Development agreement with Pfizer Inc. to develop a long term sustained release implant to deliver latanoprost for patients with ocular hypertension and glaucoma. This collaboration is focused on developing a bioerodible version of pSivida's proprietary Durasert? technology designed to be injected into the subconjunctival space of the eye.
pSivida is developing a series of additional miniaturized, bioerodible sustained release technologies to deliver a range of proteins and small drug molecules to virtually any site in the body. One of these technologies is Tethadur?, a nanostructured bioerodible material.
pSivida's intellectual property portfolio consists of 180 patents either issued or granted for acceptance, over 150 pending applications and 60 patent families.

關于我們客戶服務產品分類法律聲明
主站蜘蛛池模板: 91导航在线观看 | 亚洲va国产日韩欧美精品 | 日本高清天码一区在线播放 | 么公又大又硬又粗又爽的视频 | 亚洲欧美另类自拍第一页 | 国产成人精品999在线观看 | 久久成人国产精品免费 | 亚洲欧美综合图区官网 | 欧美国产日韩在线播放 | 日产精品一区二区三区免费 | 精品欧美成人高清视频在线观看 | 亚洲高清色 | 香蕉成人啪国产精品视频综合网 | 国产在线观看不卡 | 一级毛片成人免费看a | 欧美日韩中文字幕 | 国产午夜精品视频 | 国产成人综合久久精品尤物 | 在线免费国产视频 | 欧美日韩国产中文字幕 | 国产女上位 | 欧美一区二区三区视视频 | 久久综合精品国产一区二区三区 | 国产精品国产三级国产 | 91精品久久久 | 国产精品成人一区二区1 | 一级毛片真人不卡免费播 | 欧美日韩精品一区二区 | 久久精品国产999久久久 | 一级一级一级毛片免费毛片 | 日韩欧美国产高清 | 精品免费久久久久国产一区 | 国产精品久久久久久久久 | 日本a级精品一区二区三区 日本不卡视频一区二区三区 | 欧美激情一区二区三区四区 | 日韩欧美一区二区在线 | 日韩区在线 | 国内精品91久久久久 | 欧美日韩综合精品一区二区三区 | 黑人一区二区三区中文字幕 | 国内久久 |